Application of hericium erinaceus polysaccharide
Through the use of Monkey Mushroom Polysaccharide treatment, the problem of bile secretion disorder in weightless environments was solved, and the regulation of bile acid metabolism and the relief of constipation symptoms were achieved.
Patent Information
- Application Number
- CN202311853141.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-29
- Publication Date
- 2025-07-01
AI Technical Summary
In long-term weightless environments, bile secretion in humans or animals will be disordered, and there are currently no effective treatment measures.
The polysaccharide of Monkey Mushroom, with the molecular formula C15H10O6, is used as a drug to treat bile disorders and is administered to the patient by oral or other dosage form.
Monkey mushroom polysaccharide can regulate bile disorders, especially achieve bidirectional regulation of the main disordered components of bile, significantly improve bile acid metabolism disorders, and relieve symptoms such as constipation.
Smart Images
Figure CN120227389A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of treating bile disorders, and particularly relates to the use of a polysaccharide from Hericium erinaceus. Background Art
[0002] Bile acids (BAs), also known as 24-carbon steroids, are the main components of bile. They are a general term for a class of cholanic acids synthesized from cholesterol in the liver and play an important role in lipid metabolism and provide a certain protection to the enterohepatic circulation system. Bile acids can be classified into free and conjugated types according to their structure. Free bile acids include cholic acid, deoxycholic acid, chenodeoxycholic acid, and lithocholic acid. Conjugated bile acids are the products of conjugation of free bile acids with glycine or taurine, mainly including glycocholic acid, glycochenodeoxycholic acid, taurocholic acid, and taurochenodeoxycholic acid, etc. Bile acids can be divided into two types according to their origin: primary bile acid and secondary bile acid. Bile acids directly synthesized from cholesterol in hepatocytes are called primary bile acids, including cholic acid, chenodeoxycholic acid, and their conjugation products with glycine or taurine. Primary bile acids are acted upon by bacteria in the intestine, and the bile acids generated after 7α-hydroxyl deoxygenation are called secondary bile acids. Secondary bile acids mainly include deoxycholic acid and lithocholic acid and their conjugation products with glycine or taurine.
[0003] Primary bile acids are synthesized in the liver and excreted into the intestine through bile. Most bile acids are absorbed at the terminal ileum and re-enter the liver. A small part reaches the colon and undergoes fermentation by intestinal microorganisms to produce secondary bile acids, which are absorbed through the portal vein and re-enter the liver. Bile acids can be acetylated by glycine or taurine in the liver to form conjugated bile acids. The enterohepatic circulation of bile acids plays an important role in lipid metabolism, vitamin absorption, intestinal mucosal barrier integrity, glycogen synthesis, immune regulation, and intestinal flora composition. It is also a regulator of cholesterol metabolism enzymes. The concentration of bile acids in the blood is relatively stable, and when the homeostasis of the bile acid concentration in the blood is disrupted, it will affect human health.
[0004] When living in a long-term weightless environment, the bile secretion of humans or animals will be disordered, but there is currently no effective treatment measure. Summary of the Invention
[0005] The object of the present invention is to solve the problem of treating bile acid disorders caused by weightlessness.
[0006] The object of the present invention is achieved by adopting the following technical solution:
[0007] The use of a polysaccharide from Hericium erinaceus, the molecular formula of the polysaccharide from Hericium erinaceus is C15H10O6, and it is used for treating bile disorders.
[0008] Preferably, the usage amount of the agamidosteosarcoma polysaccharide in the agamidosteosarcoma polysaccharide is 1 mg / kg / day.
[0009] Preferably, the Monilo Polysaccharide is used to treat bile acid (CA) secretion disorder.
[0010] Preferably, the enoki mushroom polysaccharide is used to treat glycohyodeoxycholic acid (GHDCA) secretion disorder.
[0011] Preferably, the enoki mushroom polysaccharide is used to treat tauro-α-muricholic acid (T-α-MCA) secretion disorder.
[0012] Preferably, the enoki mushroom polysaccharide is used to treat tauro-β-muricholic acid (T-β-MCA) secretion disorder.
[0013] Preferably, the dosage form of the Monilo Polysaccharide includes one of granules, capsules, injections, lozenges, food, and beverages.
[0014] Compared with the prior art, the beneficial effects of the present invention are: bile disorder can be regulated by taking Monilo Polysaccharide, and in particular, bidirectional regulation of the main disorder components of bile can be achieved. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 This is a bile acid CA comparison table of the embodiments of the present invention;
[0016] Figure 2 This is a comparison table of α-muricholic acid α-MCA in the embodiments of the present invention;
[0017] Figure 3 This is a comparison table of tauro-α-muricholic acid / tauro-β-muricholic acid T-α-MCA / T-β-MCA in the embodiments of the present invention;
[0018] Figure 4 This is a comparison table of glycohyodeoxycholic acid (GHDCA) in the examples of the present invention;
[0019] Figure 5 This is a comparison table of 7-ketodehydrocholic acid 7-DHCA in the examples of the present invention;
[0020] Figure 6 This is a comparison table of ω-muricholic acid and ω-MCA in the examples of the present invention. DETAILED DESCRIPTION
[0021] The technical solution is further described below in conjunction with the accompanying drawings and specific embodiments to help understand the content of the present invention.
[0022] The present invention discloses the use of a polysaccharide from Hericium erinaceus. The molecular formula of the polysaccharide from Hericium erinaceus is C15H10O6, and it is used for the treatment of bile disorders.
[0023] Preferably, the dosage of the polysaccharide from Hericium erinaceus is 1 mg / kg / day.
[0024] Preferably, the polysaccharide from Hericium erinaceus is used for the treatment of disorders of cholic acid (CA) secretion.
[0025] Preferably, the polysaccharide from Hericium erinaceus is used for the treatment of disorders of glycohyodeoxycholic acid (GHDCA) secretion.
[0026] Preferably, the polysaccharide from Hericium erinaceus is used for the treatment of disorders of tauro-α-muricholic acid (T-α-MCA) secretion.
[0027] Preferably, the polysaccharide from Hericium erinaceus is used for the treatment of disorders of tauro-β-muricholic acid (T-β-MCA) secretion.
[0028] Preferably, the dosage form of the polysaccharide from Hericium erinaceus includes one of granules, capsules, injections, lozenges, foods, and beverages.
[0029] In order to verify the effectiveness of the present invention, the following experiments are specifically designed.
[0030] 1. Experimental design
[0031] Inbred male SD rats are selected as experimental animals. After 1 week of environmental adaptation feeding, they are divided into 3 groups.
[0032] a. Blank control group Con: The number n = 12. The rats in this group are fed irradiated sterile feed and intragastrically administered 1 mL of sterile water every day. 60 Irradiated sterile feed, intragastrically administered 1 mL of sterile water every day;
[0033] b. Tail-suspension control group TSS, the number n = 11. The rats in this group are fed irradiated sterile feed, intragastrically administered 1 mL of sterile water every day, the tail is suspended, the hind limbs are unloaded, and the hind feet are not stressed. 60 Irradiated sterile feed, intragastrically administered 1 mL of sterile water every day, the tail is suspended, the hind limbs are unloaded, and the hind feet are not stressed;
[0034] c. Polysaccharide from Hericium erinaceus intervention group MPS, the number n = 10. The rats in this group are fed irradiated sterile feed and intragastrically administered 1 mL of a polysaccharide from Hericium erinaceus solution at 0.03 g / kg / d body weight every day. The model rats adopt a tail-suspension weightlessness model, the tail is suspended, the hind limbs are unloaded, and the hind feet are not stressed. 60 Irradiated sterile feed, intragastrically administered 1 mL of a polysaccharide from Hericium erinaceus solution at 0.03 g / kg / d body weight every day. The model rats adopt a tail-suspension weightlessness model, the tail is suspended, the hind limbs are unloaded, and the hind feet are not stressed.
[0035] Dosage design reference: The minimum reference dosage of polysaccharide from Hericium erinaceus for humans is 0.2 g / d, and the maximum reference dosage is 0.4 g / d. In the literature reports, low-dose intervention experiments can play a role in protecting the gastrointestinal mucosa. Therefore, a medium-dose intervention was selected in this experiment, which is 0.3 g / d. Referring to the specific surface area ratio between rats and humans being 6 (the "Guidance on Estimating the Maximum Safe Starting Dose in Initial Clinical Trials of Therapeutic Drugs in Adult Healthy Volunteers" by the US FDA), and calculating based on an adult body weight of 60 kg, the gavage dosage for experimental rats is 0.3×6.7÷65 = 0.03 g / kg / d. Therefore, the intermediate value of 0.3 g / d was selected as the intervention dosage in the experiment. (Reference: Shao Mengru. Experimental Study on the Protective Effect of Polysaccharide from Hericium erinaceus on Gastrointestinal Mucosa [D]. Guangzhou University of Chinese Medicine, 2015.)
[0036] The experimental rats were sacrificed on the 31st day. After sacrifice, the blood of the rats was collected in purple EDTA-K2 blood collection tubes, and then centrifuged at 4°C and 3000 r / min for 15 min to obtain the supernatant serum. The collected serum was tested for bile acid metabolites, and the test method was liquid chromatography-tandem mass spectrometry. The instrument was ACQUITY UPLC-Xevo TQ-S, Waters Corp., Milford, MA, USA. The bile acid metabolites tested are shown in the following table.
[0037] Table 1 Names and abbreviations of the bile acids tested
[0038]
[0039] 2. Experimental results
[0040] A total of 24 bile acids were tested in the experiment, and only six bile acids had significant differences in concentration. They include: Cholic acid (CA) (see Figure 1 ), α-Muricholic acid (α-MCA) (see Figure 2 ), Tauro-α-muricholic acid / Tauro-β-muricholic acid (T-α-MCA / T-β-MCA) (see Figure 3 ), Glycohyodeoxycholic acid (GHDCA) (see Figure 4 ), 7-Ketodeoxycholic acid (7-DHCA) (see Figure 5 ), ω-Muricholic acid (ω-MCA) (see Figure 6) Among them, cholic acid and glycohyodeoxycholic acid decreased significantly under the condition of tail-suspension simulated weightlessness stress, while their serum concentrations increased significantly under the condition of polysaccharide from Hericium erinaceus intervention. The serum concentrations of α-muricholic acid and 7-ketodeoxycholic acid decreased under the condition of tail-suspension simulated weightlessness stress, but not significantly, and their serum concentrations increased significantly under the condition of polysaccharide from Hericium erinaceus intervention. The ratio of tauro-α-muricholic acid / tauro-β-muricholic acid increased significantly under the condition of tail-suspension simulated weightlessness stress, while its serum concentration decreased significantly under the condition of polysaccharide from Hericium erinaceus intervention. ω-Muricholic acid increased significantly under the condition of tail-suspension simulated weightlessness stress, and its serum concentration increased further significantly under the condition of polysaccharide from Hericium erinaceus intervention.
[0041] Cholic acid is a steroid and is the most abundant of the four main bile acids in humans. It is a powerful emulsifier. When its synthesis is insufficient, fat-soluble vitamins A, D, E, and K cannot be fully absorbed by the small intestine, leading to nutritional deficiencies of fat-soluble vitamins. Glycohyodeoxycholic acid (GHDCA) is a conjugated bile acid formed after the secondary bile acid hyodeoxycholic acid produced by intestinal microorganisms enters the liver. Hyodeoxycholic acid is considered a regulator of blood sugar balance and has the effects of preventing hyperlipidemia and atherosclerosis. α-Muricholic acid and the ratio of tauro-α-muricholic acid / tauro-β-muricholic acid are antagonists of the farnesoid X receptor and will increase in the intestines of mice resistant to high-fat diet-induced obesity, fatty liver, and diabetes. ω-Muricholic acid is a secondary bile acid produced by intestinal microbial fermentation and plays an important role in maintaining intestinal barrier function.
[0042] Results of human application: Given the difficulty of conducting batch human experiments under weightless conditions, 11 volunteers with habitual constipation and bile disorders were selected for an experiment on the effect of polysaccharide from Hericium erinaceus on regulating bile disorders. The volunteers all complained of long defecation times, generally exceeding 20 minutes, and difficult defecation. They ate foods containing polysaccharide from Hericium erinaceus (polysaccharide from Hericium erinaceus content ≥ 2.88 g) every day for 3 consecutive months. Among them, 8 people complained that their constipation condition improved, the number of bowel movements increased, and the stool shape was closer to banana-shaped stools. 3 people complained that there was no significant effect. The experiment proved that human intake of polysaccharide from Hericium erinaceus can also effectively relieve bile disorder symptoms.
[0043] In summary, combined with the weightlessness simulation experiment on mice, polysaccharide from Hericium erinaceus has a significant effect on preventing bile acid metabolism disorders caused by weightlessness stress.
[0044] The above are only examples of the present invention and are not used to limit the present invention. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principle of the present invention are included within the scope of the claims of the present invention.
Claims
1. Use of a polysaccharide from Hericium erinaceus, characterized in that, The molecular formula of the polysaccharide from Hericium erinaceus is C 15 H 10 O6, and it is used for treating biliary disorders.
2. Use of a Hericium erinaceus polysaccharide according to claim 1, characterized in that, The dosage of the Hericium erinaceus polysaccharide is 1 mg / kg / day.
3. The use of a Hericium erinaceus polysaccharide as described in claim 1, characterized in that, The Hericium erinaceus polysaccharide is used for treating the disorder of cholic acid (CA) secretion.
4. The use of a polysaccharide from Hericium erinaceus as claimed in claim 1, wherein, The Hericium erinaceus polysaccharide is used for treating the disorder of glycohyodeoxycholic acid (GHDCA) secretion.
5. Use of a Hericium erinaceus polysaccharide according to claim 1, characterized in that, The Hericium erinaceus polysaccharide is used for treating the disorder of tauro-α-muricholic acid (T-α-MCA) secretion.
6. The use of a Hericium erinaceus polysaccharide according to claim 1, characterized in that, The Hericium erinaceus polysaccharide is used for treating the disorder of tauro-β-muricholic acid (T-β-MCA) secretion.
7. Use of a Hericium erinaceus polysaccharide as described in claim 1, characterized in that, The dosage form of the Hericium erinaceus polysaccharide includes one of granules, capsules, injections, lozenges, foods, and beverages.